cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Updates in Medicine | 🔬 REDEFINE 2: in T2D + Original article link in bio 👥 3a RCT in 1206 adults with T2D (BMI ≥27, HbA1c 7–10%) 💉 Semaglutide, a glucagon-like peptide-1 (GLP-1)

While the FDAs action narrows the scope of disputed risks tied to GLP-1 medications, it does not address the gastrointestinal and vision-related injury claims that remain central to the ongoing litigation

For prescribers, accreditation is the clearest external signal that a compounding pharmacy is operating at a standard above the regulatory minimum and that independent experts have verified that claim

In fact, there are several potential dangers associated with the use of this medication

GLP-1RAs, glucagon-like peptide-1, receptor agonists

Reduced elasticity can increase the signs of aging, like wrinkles and lines in the face

Current Obesity Reports